We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Low Cost, Highly Sensitive Blood Test for Cancer Makes Regular Monitoring Affordable

By LabMedica International staff writers
Posted on 06 Dec 2022
Print article
Image: The Heatrich-BS assay can also help scientists study different subtypes of cancer for a low cost (Photo courtesy of NUS)
Image: The Heatrich-BS assay can also help scientists study different subtypes of cancer for a low cost (Photo courtesy of NUS)

Current methods of testing for cancers can suffer from a lack of sensitivity or from being too expensive to be used for regular screening. The DNA in our blood, the genetic information that tells our cells how to synthesize proteins and other important biological building blocks, is produced by different organs in our body. Cancer cells also release DNA into the bloodstream that can be detected by analyzing blood samples, known as liquid biopsies. However, sifting through all the genetic material in a sample – a method called whole-genome sequencing – can be expensive and labor intensive. Some clinicians instead target cancer-specific signatures in cell-free DNA, almost like hunting for specific faces in a large crowd of people instead of inspecting every single individual. Yet, even such methods can be imperfect. Scientists have now discovered a novel low-cost method of testing for cancers. Called the Heatrich-BS assay, the new test sequences clinical samples that have been heated in order to isolate cancer-specific signatures found in a patient’s blood.

Scientists from the National University of Singapore (NUS, Singapore) discovered a way to discard the non-informative sections in a patient’s DNA to target where most cancer-specific biomarkers are concentrated. Our DNA is made up of molecules known as nucleotides: adenine (A), thymine (T), guanine (G) and cytosine (C). Cancer-specific signatures tend to be concentrated in areas of the genome that have high repetitions of C and G nucleotides, known as CpG islands, that make up only around 1% of our genome. The team accidentally discovered that heat destroyed non-informative sections of the genome, but left CpG island largely intact. This allowed them to sequence the remaining genome and detect the presence of cancers for a minute fraction of the average market price. It costs around S$50 from start to finish, compared to other sequencing methods that can cost up to S$1,000 to conduct.

The Heatrich-BS assay has been trialed at the National Cancer Centre in Singapore, monitoring patients with colorectal cancer. By comparing the results of their blood analysis with CT scans that imaged the size of patients’ tumours, the team found that there was a high correlation between how much cancer-specific DNA was detected in a patient’s blood sample and the size of their tumours over time. The new method also provides a promising non-invasive alternative to tissue biopsies. The method has the potential to work universally across all types of cancer since they all demonstrate the property of enriching CpG islands with cancer-specific biomarkers. The assay may also help accelerate future academic research, helping scientists study different subtypes of cancer for a low cost and therefore improving the development of future cancer diagnoses and therapies. The research team is now exploring ways to commercialize the assay by partnering with pharmaceutical and biotechnology companies that can help bring the Heatrich-BS assay to market.

“When you have a S$50 test, it opens up a lot of avenues because it is affordable, so you can do the test quite regularly,” said Assistant Professor Cheow Lih Feng, pointing to the potential for their assay to be used in regular cancer monitoring. “We are getting a much more sensitive assay at almost the same costs as compared to simple protein biomarker tests. Our method really concentrates on sequencing these regions that matter the most.”

Related Links:
NUS

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.